NCT05246345|Recruiting
Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia
RAVEN
Loading search results
RAVEN
Sponsor study identifier
Secondary identifiers
OTHER · 2021-A00362-39
observational
50
1 country
14
Study Start
March 7, 2022
Actual (reported)Primary Completion
March 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
March 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The purpose of this study is to collect medical informations and samples from refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax treatment, in order to evaluate the frequency of resistance mechanisms.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 13, 2021
Actual (reported)February 18, 2022
Actual (reported)March 7, 2022
Actual (reported)March 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
March 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Frequency measurement of BCL2 gene mutations
Frequency measurement of BCL2 gene mutations in a cohort of refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax therapy
immediately after the chronic lymphocytic leukemia progression
Frequency measurement of 1q amplification
immediately after the chronic lymphocytic leukemia progression
Differential expression of candidate transcripts and proteins
immediately after the chronic lymphocytic leukemia progression
Cohort of refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax
Patients with chronic lymphocytic leukemia diagnosis according to iwCLL criteria and who are refractory and/or relapsed disease during or after venetoclax treatment; tumor samples available.
CHU d'Amiens
Amiens, France
CHU de Besançon
Besançon, France
Hopital AVICENNE
Bobigny, France
Romain GUIEZE
University Hospital, Clermont-Ferrand
First Submitted
October 13, 2021
First Posted
February 18, 2022
Study Start
March 7, 2022
Actual (reported)Primary Completion
March 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Correlation of resistance mechanisms with clinical staging
immediately after the chronic lymphocytic leukemia progression
Correlation of resistance mechanisms with genomic chronic lymphocytic leukemia features
immediately after the chronic lymphocytic leukemia progression
Progression Free Survival according to resistance mechanisms
immediately after the chronic lymphocytic leukemia progression
Contact the study team to confirm eligibility.
CHU clermont-ferrand
Clermont-Ferrand, France
CHU de Clermont Ferrand
Clermont-Ferrand, France
CHU Grenoble
Grenoble, France
CHRU de Lille
Lille, France
Centre LEON BERARD
Lyon, France
CHU de Montpellier
Montpellier, France
CHU Nancy
Nancy, France
Hopital Pitié Salpetrière
Paris, France
Hopital Haut LEVEQUE
Pessac, France
CHU de Reims
Reims, France
IUCT Oncopole
Toulouse, France
Study Completion
March 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
January 9, 2024
Record last verified: 2023-06
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: